Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALC Alcon	$87.37 +0.5%	$87.38	$80.48 ▼ $101.10	$43.08B	0.95	1.23 million shs	1.74 million shs
IDXX IDEXX Laboratories	$514.61 -0.8%	$523.58	$356.14 ▼ $549.52	$41.39B	1.54	642,698 shs	329,531 shs
MRNA Moderna	$31.26 -2.9%	$27.91	$23.15 ▼ $125.68	$12.09B	1.84	8.97 million shs	7.81 million shs
TAK Takeda Pharmaceutical	$14.42 -2.2%	$14.83	$12.80 ▼ $15.53	$45.92B	0.23	2.02 million shs	3.64 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALC Alcon	0.00%	-0.13%	+3.07%	-5.52%	-2.93%
IDXX IDEXX Laboratories	0.00%	-3.52%	-1.01%	+24.99%	+3.65%
MRNA Moderna	0.00%	-7.07%	+23.07%	+26.48%	-74.80%
TAK Takeda Pharmaceutical	0.00%	-1.70%	-3.25%	-1.80%	+5.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALC Alcon	2.7011 of 5 stars	3.4	3.0	0.8	0.0	1.2	0.8	1.3
IDXX IDEXX Laboratories	3.5863 of 5 stars	1.4	3.0	0.0	3.7	3.5	2.5	1.3
MRNA Moderna	4.2516 of 5 stars	4.0	1.0	0.0	4.6	1.8	2.5	0.6
TAK Takeda Pharmaceutical	2.0499 of 5 stars	0.0	5.0	2.5	0.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALC Alcon	2.80	Moderate Buy	$106.13	21.47% Upside
IDXX IDEXX Laboratories	2.80	Moderate Buy	$560.33	8.89% Upside
MRNA Moderna	2.04	Hold	$46.61	49.11% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest IDXX, MRNA, TAK, and ALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$580.00 ➝ $600.00
7/15/2025	ALC Alcon	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$90.00 ➝ $84.00
7/14/2025	ALC Alcon	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$100.00
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Hold
7/2/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$510.00 ➝ $540.00
7/1/2025	IDXX IDEXX Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$625.00
6/11/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $580.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	ALC Alcon	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALC Alcon	$9.91B	4.35	$5.56 per share	15.72	$43.70 per share	2.00
IDXX IDEXX Laboratories	$3.90B	10.62	$12.43 per share	41.40	$19.48 per share	26.42
MRNA Moderna	$3.14B	3.85	N/A	N/A	$28.33 per share	1.10
TAK Takeda Pharmaceutical	$30.09B	1.53	$3.18 per share	4.54	$14.39 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALC Alcon	$1.02B	$2.25	38.83	26.56	2.24	11.28%	6.95%	4.92%	8/19/2025 (Estimated)
IDXX IDEXX Laboratories	$887.87M	$10.82	47.56	37.89	3.74	22.76%	57.35%	26.97%	8/4/2025 (Confirmed)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	8/1/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	65.55	8.74	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest IDXX, MRNA, TAK, and ALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	IDXX IDEXX Laboratories	$3.28	N/A	N/A	N/A	$1.06 billion	N/A
8/1/2025	Q2 2025	MRNA Moderna	-$2.97	N/A	N/A	N/A	$116.26 million	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/13/2025	Q1 2025	ALC Alcon	$0.77	$0.73	-$0.04	$0.70	$2.52 billion	$2.33 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	$2.96	+$0.03	$2.96	$998.25 million	$998.43 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALC Alcon	N/A	N/A	N/A	N/A	4 Years
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.81%	N/A	250.00%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALC Alcon	0.21	2.70	1.66
IDXX IDEXX Laboratories	0.31	1.16	0.81
MRNA Moderna	N/A	4.22	4.14
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALC Alcon	53.86%
IDXX IDEXX Laboratories	87.84%
MRNA Moderna	75.33%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ALC Alcon	1.52%
IDXX IDEXX Laboratories	0.98%
MRNA Moderna	11.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALC Alcon	25,599	493.24 million	485.75 million	Optionable
IDXX IDEXX Laboratories	11,000	80.42 million	79.63 million	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

IDXX, MRNA, TAK, and ALC Headlines

Recent News About These Companies

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Cerity Partners LLC

3 hours ago | marketbeat.com

Envestnet Asset Management Inc. Has $13.25 Million Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

July 19 at 3:35 AM | marketbeat.com

IDSA Updates Guidelines on Complicated UTIs

July 18 at 7:43 PM | medscape.comM

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

July 17 at 12:03 PM | seekingalpha.com

Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton

July 15, 2025 | tipranks.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in ...

July 14, 2025 | gurufocus.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

July 14, 2025 | businesswire.com

Takeda: Positives And Negatives Offset Each Other

July 11, 2025 | seekingalpha.com

Vontobel Holding Ltd. Acquires New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

July 9, 2025 | marketbeat.com

Crossmark Global Holdings Inc. Purchases 186,349 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Takeda Completes Treasury Share Disposal with Minor Adjustments

July 8, 2025 | tipranks.com

Lupin gets USFDA approval for post-eye surgery drug

July 2, 2025 | indiainfoline.comI

Takeda Pharmaceutical Co. (NYSE:TAK) Stock Position Raised by Sequoia Financial Advisors LLC

July 1, 2025 | marketbeat.com

FDA Approves Takeda’s Gammagard Liquid ERC

June 30, 2025 | contractpharma.comC

Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - What's Next?

June 30, 2025 | marketbeat.com

Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease

June 28, 2025 | medscape.comM

Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine

June 28, 2025 | gmanetwork.comG

Sun Pharma appoints Richard Ascroft as North American CEO

June 27, 2025 | emjreviews.comE

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug

June 25, 2025 | thehindu.com

Sun Pharma Announces Appointment of Richard Ascroft as CEO North America

June 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why

IDXX, MRNA, TAK, and ALC Company Descriptions

Alcon NYSE:ALC

$87.37 +0.41 (+0.47%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$87.34 -0.03 (-0.03%)

As of 07/18/2025 04:39 PM Eastern

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

IDEXX Laboratories NASDAQ:IDXX

$514.61 -4.10 (-0.79%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$506.95 -7.66 (-1.49%)

As of 07/18/2025 07:20 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Moderna NASDAQ:MRNA

$31.26 -0.94 (-2.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$31.26 -0.01 (-0.02%)

As of 07/18/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Takeda Pharmaceutical NYSE:TAK

$14.42 -0.32 (-2.17%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$14.42 +0.01 (+0.03%)

As of 07/18/2025 04:53 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time